Opendata, web and dolomites

SupraRNA SIGNED

A Comprehensive Supramolecular Approach for an RNA vaccine for Influenza A (H1N1)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SupraRNA project word cloud

Explore the words cloud of the SupraRNA project. It provides you a very rough idea of what is the project "SupraRNA" about.

declared    connected    optimum    therapeutic    messenger    scope    oxy    parts    bonding    world    central    covalent    peg    moiety    efficacy    protect    surface    enhanced    disulfide    peptide    enzymatic    lines    ethylene    redox    poly    afforded    hemagglutinin    transfection    epidemic    hydrolysis    vaccines    rna    pi    times    strand    intracellular    groups    tat    nucleic    caused    hydrogen    alternatively    promise    immense    gene    disease    molecule    pathogens    influenza    pr8    co    hydrophilic    macrophage    vehicle    threat    assemblies    glycol    steric    infection    seasonally    stabilization    respiratory    amphiphile    platform    acute    nanoassembly    virus    circulate    functionalized    environments    chains    health    cell    globally    biological    exploring    h1n1    strain    viruses    nature    employed    prevention    lay    healthcare    decorated    conjugation    groundwork    supramolecular    class    bond    responsive    assembly    persistent    mrna    vaccination    aryl    transport    vector    self    efficient    chain    acids    manufacturing    incorporation    model    oligo    seasonal   

Project "SupraRNA" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF BIRMINGHAM 

Organization address
address: Edgbaston
city: BIRMINGHAM
postcode: B15 2TT
website: www.bham.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 212˙933 €
 EC max contribution 212˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) coordinator 212˙933.00

Map

 Project objective

*The development of vaccines is key for disease prevention, and is a major focus globally in the healthcare sector. Seasonal influenza is an acute respiratory infection caused by influenza viruses which circulate in all parts of the world. Seasonally, it remains a persistent health threat and has been declared an epidemic in some states. Typical vaccines have been less effective against rapidly evolving pathogens such as influenza. A new class of vaccines based on nucleic acids, namely RNA, have recently been developed and show immense promise due to their robust nature, short manufacturing times and enhanced efficacy. Here we propose an RNA delivery system based on a supramolecular assembly approach for the vaccination of influenza A H1N1 strain. Specifically, a π-amphiphile will be used as the platform molecule for covalent RNA conjugation and delivery. A messenger RNA (mRNA) targeting the hemagglutinin (HA) gene from a model influenza virus strain will be employed as the therapeutic (H1N1/PR8-HA). The central π-amphiphile moiety will be functionalized with the mRNA strand via a redox responsive disulfide bond, and hydrophilic oligo-oxy aryl groups connected via a hydrogen bonding unit to promote self-assembly. Steric stabilization will be afforded to the surface decorated mRNA to protect from enzymatic hydrolysis in the complex biological environments, through co-assembly with an analogue π-amphiphile which has been alternatively decorated with poly(ethylene glycol) (PEG) chains. Efficient intracellular transport of the delivery vehicle to achieve optimum mRNA transfection will be achieved through the incorporation of a TAT-peptide on the PEG chain end. The therapeutic efficacy of the nanoassembly will be evaluated through transfection efficacy in macrophage cell lines. Overall, this proposal aims to lay the groundwork for extending the scope of RNA vaccines by exploring the potential of supramolecular assemblies as a delivery vector.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUPRARNA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUPRARNA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MathematicsAnalogies (2019)

Mathematics Analogies

Read More